Selected research
Market Outlook & Growth Opportunities
Global Lurasidone Market Outlook and Growth Opportunities 2026
Market perspective
The global Lurasidone market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a compound annual growth rate (CAGR) of % over 2026-2032.
The North America market for Lurasidone is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.
The Europe market for Lurasidone is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.
Read the full market overview
The Asia Pacific market for Lurasidone is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.
In China, the Lurasidone market is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.
Major global companies in the Lurasidone market include Zhejiang Hisun Pharmaceutical Co., Ltd., Sumitomo Dainippon Pharma Co., Ltd., Square Pharmaceuticals Ltd., RemedyRepack,Inc., Incepta Pharmaceuticals Ltd., Healthcare Pharmaceuticals Limited, Bushu Pharmaceutical, LTD. and Angelini Holding S.p.A., among others. In 2025, the top three vendors together accounted for approximately % of global revenue.
This report provides an overview of the global Lurasidone market in terms of sales, revenue, and price, analyzing global market trends using historical revenue and sales data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.
The study covers key producers of Lurasidone and sales in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.
The report also presents Lurasidone sales, revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.
In addition, the report analyzes segment data by Type and Application—covering sales, revenue, and price—for 2021-2032, and evaluates and forecasts the Lurasidone market size, projected growth trends, production technologies, key applications, and end-use industries.
Lurasidone Segment by Company
Zhejiang Hisun Pharmaceutical Co., Ltd.
Sumitomo Dainippon Pharma Co., Ltd.
Square Pharmaceuticals Ltd.
RemedyRepack,Inc.
Incepta Pharmaceuticals Ltd.
Healthcare Pharmaceuticals Limited
Bushu Pharmaceutical, LTD.
Angelini Holding S.p.A.
Lurasidone Segment by Type
120mg/tablet
20mg/tablet
40mg/tablet
60mg/tablet
80mg/tablet
Lurasidone Segment by Application
Hospital
Psychological Clinic
Others
Lurasidone Segment by Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Netherlands
Nordic Countries
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Southeast Asia
South America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
Study Objectives
1. To analyze and research the global Lurasidone status and future forecast, involving, sales, revenue, growth rate (CAGR), market share, historical and forecast.
2. To present the key manufacturers, sales, revenue, market share, and Recent Developments.
3. To split the breakdown data by regions, type, manufacturers, and Application.
4. To analyze the global and key regions Lurasidone market potential and advantage, opportunity and challenge, restraints, and risks.
5. To identify Lurasidone significant trends, drivers, influence factors in global and regions.
6. To analyze Lurasidone competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Lurasidone market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Lurasidone and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market.
5. This report helps stakeholders to gain insights into which regions to target globally.
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Lurasidone.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Provides an overview of the Lurasidone market, including product definition, global market growth prospects, sales value, sales volume, and average price forecasts (2021-2032).
Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Lurasidone industry.
Chapter 3: Detailed analysis of Lurasidone manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Sales and value of Lurasidone in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 7: Sales and value of Lurasidone in country level. It provides sigmate data by type, and by application for each country/region.
Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 10: Concluding Insights.
More report detail
Tables and figures
Scope & coverage.
Types
- 120mg/tablet
- 20mg/tablet
- 40mg/tablet
- 60mg/tablet
- 80mg/tablet
Applications
- Hospital
- Psychological Clinic
- Others
Companies covered
- Zhejiang Hisun Pharmaceutical Co., Ltd.
- Sumitomo Dainippon Pharma Co., Ltd.
- Square Pharmaceuticals Ltd.
- RemedyRepack,Inc.
- Incepta Pharmaceuticals Ltd.
- Healthcare Pharmaceuticals Limited
- Bushu Pharmaceutical, LTD.
- Angelini Holding S.p.A.
Inside the report.
1 Market Overview
- 1.1 Product Definition
- 1.2 Global Market Growth Prospects
- 1.2.1 Global Lurasidone Sales Value (2021-2032)
- 1.2.2 Global Lurasidone Sales Volume (2021-2032)
- 1.2.3 Global Lurasidone Sales Average Price (2021-2032)
- 1.3 Assumptions and Limitations
- 1.4 Study Goals and Objectives
2 Lurasidone Market Dynamics
- 2.1 Lurasidone Industry Trends
- 2.2 Lurasidone Industry Drivers
- 2.3 Lurasidone Industry Opportunities and Challenges
- 2.4 Lurasidone Industry Restraints
3 Lurasidone Market by Company
- 3.1 Global Lurasidone Company Revenue Ranking in 2025
- 3.2 Global Lurasidone Revenue by Company (2021-2026)
- 3.3 Global Lurasidone Sales Volume by Company (2021-2026)
- 3.4 Global Lurasidone Average Price by Company (2021-2026)
- 3.5 Global Lurasidone Company Ranking (2024-2026)
- 3.6 Global Lurasidone Company Manufacturing Base and Headquarters
- 3.7 Global Lurasidone Company Product Type and Application
- 3.8 Global Lurasidone Company Establishment Date
- 3.9 Market Competitive Analysis
- 3.9.1 Global Lurasidone Market Concentration Ratio (CR5 and HHI)
- 3.9.2 Global Top 5 and 10 Company Market Share by Revenue in 2025
- 3.9.3 2025 Lurasidone Tier 1, Tier 2, and Tier 3 Companies
- 3.10 Mergers and Acquisitions Expansion
4 Lurasidone Market by Type
- 4.1 Lurasidone Type Introduction
- 4.1.1 120mg/tablet
- 4.1.2 20mg/tablet
- 4.1.3 40mg/tablet
- 4.1.4 60mg/tablet
- 4.1.5 80mg/tablet
- 4.2 Global Lurasidone Sales Volume by Type
- 4.2.1 Global Lurasidone Sales Volume by Type (2021 VS 2025 VS 2032)
- 4.2.2 Global Lurasidone Sales Volume by Type (2021-2032)
- 4.2.3 Global Lurasidone Sales Volume Share by Type (2021-2032)
- 4.3 Global Lurasidone Sales Value by Type
- 4.3.1 Global Lurasidone Sales Value by Type (2021 VS 2025 VS 2032)
- 4.3.2 Global Lurasidone Sales Value by Type (2021-2032)
- 4.3.3 Global Lurasidone Sales Value Share by Type (2021-2032)
5 Lurasidone Market by Application
- 5.1 Lurasidone Application Introduction
- 5.1.1 Hospital
- 5.1.2 Psychological Clinic
- 5.1.3 Others
- 5.2 Global Lurasidone Sales Volume by Application
- 5.2.1 Global Lurasidone Sales Volume by Application (2021 VS 2025 VS 2032)
- 5.2.2 Global Lurasidone Sales Volume by Application (2021-2032)
- 5.2.3 Global Lurasidone Sales Volume Share by Application (2021-2032)
- 5.3 Global Lurasidone Sales Value by Application
- 5.3.1 Global Lurasidone Sales Value by Application (2021 VS 2025 VS 2032)
- 5.3.2 Global Lurasidone Sales Value by Application (2021-2032)
- 5.3.3 Global Lurasidone Sales Value Share by Application (2021-2032)
6 Lurasidone Regional Sales and Value Analysis
- 6.1 Global Lurasidone Sales by Region: 2021 VS 2025 VS 2032
- 6.2 Global Lurasidone Sales by Region (2021-2032)
- 6.2.1 Global Lurasidone Sales by Region: 2021-2026
- 6.2.2 Global Lurasidone Sales by Region (2027-2032)
- 6.3 Global Lurasidone Sales Value by Region: 2021 VS 2025 VS 2032
- 6.4 Global Lurasidone Sales Value by Region (2021-2032)
- 6.4.1 Global Lurasidone Sales Value by Region: 2021-2026
- 6.4.2 Global Lurasidone Sales Value by Region (2027-2032)
- 6.5 Global Lurasidone Market Price Analysis by Region (2021-2026)
- 6.6 North America
- 6.6.1 North America Lurasidone Sales Value (2021-2032)
- 6.6.2 North America Lurasidone Sales Value Share by Country, 2025 VS 2032
- 6.7 Europe
- 6.7.1 Europe Lurasidone Sales Value (2021-2032)
- 6.7.2 Europe Lurasidone Sales Value Share by Country, 2025 VS 2032
- 6.8 Asia-Pacific
- 6.8.1 Asia-Pacific Lurasidone Sales Value (2021-2032)
- 6.8.2 Asia-Pacific Lurasidone Sales Value Share by Country, 2025 VS 2032
- 6.9 South America
- 6.9.1 South America Lurasidone Sales Value (2021-2032)
- 6.9.2 South America Lurasidone Sales Value Share by Country, 2025 VS 2032
- 6.10 Middle East & Africa
- 6.10.1 Middle East & Africa Lurasidone Sales Value (2021-2032)
- 6.10.2 Middle East & Africa Lurasidone Sales Value Share by Country, 2025 VS 2032
7 Lurasidone Country-level Sales and Value Analysis
- 7.1 Global Lurasidone Sales by Country: 2021 VS 2025 VS 2032
- 7.2 Global Lurasidone Sales Value by Country: 2021 VS 2025 VS 2032
- 7.3 Global Lurasidone Sales by Country (2021-2032)
- 7.3.1 Global Lurasidone Sales by Country (2021-2026)
- 7.3.2 Global Lurasidone Sales by Country (2027-2032)
- 7.4 Global Lurasidone Sales Value by Country (2021-2032)
- 7.4.1 Global Lurasidone Sales Value by Country (2021-2026)
- 7.4.2 Global Lurasidone Sales Value by Country (2027-2032)
- 7.5 USA
- 7.5.1 USA Lurasidone Sales Value Growth Rate (2021-2032)
- 7.5.2 USA Lurasidone Sales Value Share by Type, 2025 VS 2032
- 7.5.3 USA Lurasidone Sales Value Share by Application, 2025 VS 2032
- 7.6 Canada
- 7.6.1 Canada Lurasidone Sales Value Growth Rate (2021-2032)
- 7.6.2 Canada Lurasidone Sales Value Share by Type, 2025 VS 2032
- 7.6.3 Canada Lurasidone Sales Value Share by Application, 2025 VS 2032
- 7.7 Mexico
- 7.6.1 Mexico Lurasidone Sales Value Growth Rate (2021-2032)
- 7.6.2 Mexico Lurasidone Sales Value Share by Type, 2025 VS 2032
- 7.6.3 Mexico Lurasidone Sales Value Share by Application, 2025 VS 2032
- 7.8 Germany
- 7.8.1 Germany Lurasidone Sales Value Growth Rate (2021-2032)
- 7.8.2 Germany Lurasidone Sales Value Share by Type, 2025 VS 2032
- 7.8.3 Germany Lurasidone Sales Value Share by Application, 2025 VS 2032
- 7.9 France
- 7.9.1 France Lurasidone Sales Value Growth Rate (2021-2032)
- 7.9.2 France Lurasidone Sales Value Share by Type, 2025 VS 2032
- 7.9.3 France Lurasidone Sales Value Share by Application, 2025 VS 2032
- 7.10 U.K.
- 7.10.1 U.K. Lurasidone Sales Value Growth Rate (2021-2032)
- 7.10.2 U.K. Lurasidone Sales Value Share by Type, 2025 VS 2032
- 7.10.3 U.K. Lurasidone Sales Value Share by Application, 2025 VS 2032
- 7.11 Italy
- 7.11.1 Italy Lurasidone Sales Value Growth Rate (2021-2032)
- 7.11.2 Italy Lurasidone Sales Value Share by Type, 2025 VS 2032
- 7.11.3 Italy Lurasidone Sales Value Share by Application, 2025 VS 2032
- 7.12 Spain
- 7.12.1 Spain Lurasidone Sales Value Growth Rate (2021-2032)
- 7.12.2 Spain Lurasidone Sales Value Share by Type, 2025 VS 2032
- 7.12.3 Spain Lurasidone Sales Value Share by Application, 2025 VS 2032
- 7.13 Russia
- 7.13.1 Russia Lurasidone Sales Value Growth Rate (2021-2032)
- 7.13.2 Russia Lurasidone Sales Value Share by Type, 2025 VS 2032
- 7.13.3 Russia Lurasidone Sales Value Share by Application, 2025 VS 2032
- 7.14 Netherlands
- 7.14.1 Netherlands Lurasidone Sales Value Growth Rate (2021-2032)
- 7.14.2 Netherlands Lurasidone Sales Value Share by Type, 2025 VS 2032
- 7.14.3 Netherlands Lurasidone Sales Value Share by Application, 2025 VS 2032
- 7.15 Nordic Countries
- 7.15.1 Nordic Countries Lurasidone Sales Value Growth Rate (2021-2032)
- 7.15.2 Nordic Countries Lurasidone Sales Value Share by Type, 2025 VS 2032
- 7.15.3 Nordic Countries Lurasidone Sales Value Share by Application, 2025 VS 2032
- 7.16 China
- 7.16.1 China Lurasidone Sales Value Growth Rate (2021-2032)
- 7.16.2 China Lurasidone Sales Value Share by Type, 2025 VS 2032
- 7.16.3 China Lurasidone Sales Value Share by Application, 2025 VS 2032
- 7.17 Japan
- 7.17.1 Japan Lurasidone Sales Value Growth Rate (2021-2032)
- 7.17.2 Japan Lurasidone Sales Value Share by Type, 2025 VS 2032
- 7.17.3 Japan Lurasidone Sales Value Share by Application, 2025 VS 2032
- 7.18 South Korea
- 7.18.1 South Korea Lurasidone Sales Value Growth Rate (2021-2032)
- 7.18.2 South Korea Lurasidone Sales Value Share by Type, 2025 VS 2032
- 7.18.3 South Korea Lurasidone Sales Value Share by Application, 2025 VS 2032
- 7.19 India
- 7.19.1 India Lurasidone Sales Value Growth Rate (2021-2032)
- 7.19.2 India Lurasidone Sales Value Share by Type, 2025 VS 2032
- 7.19.3 India Lurasidone Sales Value Share by Application, 2025 VS 2032
- 7.20 Australia
- 7.20.1 Australia Lurasidone Sales Value Growth Rate (2021-2032)
- 7.20.2 Australia Lurasidone Sales Value Share by Type, 2025 VS 2032
- 7.20.3 Australia Lurasidone Sales Value Share by Application, 2025 VS 2032
- 7.21 Southeast Asia
- 7.21.1 Southeast Asia Lurasidone Sales Value Growth Rate (2021-2032)
- 7.21.2 Southeast Asia Lurasidone Sales Value Share by Type, 2025 VS 2032
- 7.21.3 Southeast Asia Lurasidone Sales Value Share by Application, 2025 VS 2032
- 7.22 Brazil
- 7.22.1 Brazil Lurasidone Sales Value Growth Rate (2021-2032)
- 7.22.2 Brazil Lurasidone Sales Value Share by Type, 2025 VS 2032
- 7.22.3 Brazil Lurasidone Sales Value Share by Application, 2025 VS 2032
- 7.23 Argentina
- 7.23.1 Argentina Lurasidone Sales Value Growth Rate (2021-2032)
- 7.23.2 Argentina Lurasidone Sales Value Share by Type, 2025 VS 2032
- 7.23.3 Argentina Lurasidone Sales Value Share by Application, 2025 VS 2032
- 7.24 Chile
- 7.24.1 Chile Lurasidone Sales Value Growth Rate (2021-2032)
- 7.24.2 Chile Lurasidone Sales Value Share by Type, 2025 VS 2032
- 7.24.3 Chile Lurasidone Sales Value Share by Application, 2025 VS 2032
- 7.25 Colombia
- 7.25.1 Colombia Lurasidone Sales Value Growth Rate (2021-2032)
- 7.25.2 Colombia Lurasidone Sales Value Share by Type, 2025 VS 2032
- 7.25.3 Colombia Lurasidone Sales Value Share by Application, 2025 VS 2032
- 7.26 Peru
- 7.26.1 Peru Lurasidone Sales Value Growth Rate (2021-2032)
- 7.26.2 Peru Lurasidone Sales Value Share by Type, 2025 VS 2032
- 7.26.3 Peru Lurasidone Sales Value Share by Application, 2025 VS 2032
- 7.27 Saudi Arabia
- 7.27.1 Saudi Arabia Lurasidone Sales Value Growth Rate (2021-2032)
- 7.27.2 Saudi Arabia Lurasidone Sales Value Share by Type, 2025 VS 2032
- 7.27.3 Saudi Arabia Lurasidone Sales Value Share by Application, 2025 VS 2032
- 7.28 Israel
- 7.28.1 Israel Lurasidone Sales Value Growth Rate (2021-2032)
- 7.28.2 Israel Lurasidone Sales Value Share by Type, 2025 VS 2032
- 7.28.3 Israel Lurasidone Sales Value Share by Application, 2025 VS 2032
- 7.29 UAE
- 7.29.1 UAE Lurasidone Sales Value Growth Rate (2021-2032)
- 7.29.2 UAE Lurasidone Sales Value Share by Type, 2025 VS 2032
- 7.29.3 UAE Lurasidone Sales Value Share by Application, 2025 VS 2032
- 7.30 Turkey
- 7.30.1 Turkey Lurasidone Sales Value Growth Rate (2021-2032)
- 7.30.2 Turkey Lurasidone Sales Value Share by Type, 2025 VS 2032
- 7.30.3 Turkey Lurasidone Sales Value Share by Application, 2025 VS 2032
- 7.31 Iran
- 7.31.1 Iran Lurasidone Sales Value Growth Rate (2021-2032)
- 7.31.2 Iran Lurasidone Sales Value Share by Type, 2025 VS 2032
- 7.31.3 Iran Lurasidone Sales Value Share by Application, 2025 VS 2032
- 7.32 Egypt
- 7.32.1 Egypt Lurasidone Sales Value Growth Rate (2021-2032)
- 7.32.2 Egypt Lurasidone Sales Value Share by Type, 2025 VS 2032
- 7.32.3 Egypt Lurasidone Sales Value Share by Application, 2025 VS 2032
8 Company Profiles
- 8.1 Zhejiang Hisun Pharmaceutical Co., Ltd.
- 8.1.1 Zhejiang Hisun Pharmaceutical Co., Ltd. Company Information
- 8.1.2 Zhejiang Hisun Pharmaceutical Co., Ltd. Business Overview
- 8.1.3 Zhejiang Hisun Pharmaceutical Co., Ltd. Lurasidone Sales, Value and Gross Margin (2021-2026)
- 8.1.4 Zhejiang Hisun Pharmaceutical Co., Ltd. Lurasidone Product Portfolio
- 8.1.5 Zhejiang Hisun Pharmaceutical Co., Ltd. Recent Developments
- 8.2 Sumitomo Dainippon Pharma Co., Ltd.
- 8.2.1 Sumitomo Dainippon Pharma Co., Ltd. Company Information
- 8.2.2 Sumitomo Dainippon Pharma Co., Ltd. Business Overview
- 8.2.3 Sumitomo Dainippon Pharma Co., Ltd. Lurasidone Sales, Value and Gross Margin (2021-2026)
- 8.2.4 Sumitomo Dainippon Pharma Co., Ltd. Lurasidone Product Portfolio
- 8.2.5 Sumitomo Dainippon Pharma Co., Ltd. Recent Developments
- 8.3 Square Pharmaceuticals Ltd.
- 8.3.1 Square Pharmaceuticals Ltd. Company Information
- 8.3.2 Square Pharmaceuticals Ltd. Business Overview
- 8.3.3 Square Pharmaceuticals Ltd. Lurasidone Sales, Value and Gross Margin (2021-2026)
- 8.3.4 Square Pharmaceuticals Ltd. Lurasidone Product Portfolio
- 8.3.5 Square Pharmaceuticals Ltd. Recent Developments
- 8.4 RemedyRepack,Inc.
- 8.4.1 RemedyRepack,Inc. Company Information
- 8.4.2 RemedyRepack,Inc. Business Overview
- 8.4.3 RemedyRepack,Inc. Lurasidone Sales, Value and Gross Margin (2021-2026)
- 8.4.4 RemedyRepack,Inc. Lurasidone Product Portfolio
- 8.4.5 RemedyRepack,Inc. Recent Developments
- 8.5 Incepta Pharmaceuticals Ltd.
- 8.5.1 Incepta Pharmaceuticals Ltd. Company Information
- 8.5.2 Incepta Pharmaceuticals Ltd. Business Overview
- 8.5.3 Incepta Pharmaceuticals Ltd. Lurasidone Sales, Value and Gross Margin (2021-2026)
- 8.5.4 Incepta Pharmaceuticals Ltd. Lurasidone Product Portfolio
- 8.5.5 Incepta Pharmaceuticals Ltd. Recent Developments
- 8.6 Healthcare Pharmaceuticals Limited
- 8.6.1 Healthcare Pharmaceuticals Limited Company Information
- 8.6.2 Healthcare Pharmaceuticals Limited Business Overview
- 8.6.3 Healthcare Pharmaceuticals Limited Lurasidone Sales, Value and Gross Margin (2021-2026)
- 8.6.4 Healthcare Pharmaceuticals Limited Lurasidone Product Portfolio
- 8.6.5 Healthcare Pharmaceuticals Limited Recent Developments
- 8.7 Bushu Pharmaceutical, LTD.
- 8.7.1 Bushu Pharmaceutical, LTD. Company Information
- 8.7.2 Bushu Pharmaceutical, LTD. Business Overview
- 8.7.3 Bushu Pharmaceutical, LTD. Lurasidone Sales, Value and Gross Margin (2021-2026)
- 8.7.4 Bushu Pharmaceutical, LTD. Lurasidone Product Portfolio
- 8.7.5 Bushu Pharmaceutical, LTD. Recent Developments
- 8.8 Angelini Holding S.p.A.
- 8.8.1 Angelini Holding S.p.A. Company Information
- 8.8.2 Angelini Holding S.p.A. Business Overview
- 8.8.3 Angelini Holding S.p.A. Lurasidone Sales, Value and Gross Margin (2021-2026)
- 8.8.4 Angelini Holding S.p.A. Lurasidone Product Portfolio
- 8.8.5 Angelini Holding S.p.A. Recent Developments
9 Value Chain and Sales Channels Analysis
- 9.1 Lurasidone Value Chain Analysis
- 9.1.1 Lurasidone Key Raw Materials
- 9.1.2 Raw Materials Key Suppliers
- 9.1.3 Manufacturing Cost Structure
- 9.1.4 Lurasidone Sales Mode & Process
- 9.2 Lurasidone Sales Channels Analysis
- 9.2.1 Direct Comparison with Distribution Share
- 9.2.2 Lurasidone Distributors
- 9.2.3 Lurasidone Customers
10 Concluding Insights
11 Appendix
- 11.1 Reasons for Doing This Study
- 11.2 Research Methodology
- 11.3 Research Process
- 11.4 Authors List of This Report
- 11.5 Data Source
- 11.5.1 Secondary Sources
- 11.5.2 Primary Sources
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst